Pass on the Pink Pill – Or Pass Out!
In 2015, the FDA buckled to pressure from a savvy astroturf campaign and approved the female libido drug flibanserin (brand name: Addyi). In response, the National Women’s Health Network launched the “Pass on the Pink Pill – Or Pass Out” campaign to warn women of the marginal benefits and serious side effects of the “pink pill”—complications like dangerously low blood pressure, dizziness, and even sudden loss of consciousness.
Photos taken at the 8th Annual Barbara Seaman Awards for Activism in Women’s Health event.
The NWHN has issued a report card, “Addyi One Year Later: What’s the Score?” The report grades the manufacturer, Valeant Pharmaceuticals, upon careful review of their performance. After one year, we’ve seen a lot of broken promises, studies that were never conducted, and faulty training practices.
Rather than rely on drug company marketing, NWHN recommends that women educate themselves and pass on the pink pill.
Resources
Addyi Timeline Fatchseet
Want to know how this bogus drug got on the market?
Share PDF:
Clinical Trials Fatchseet
Get more information about the faulty clinical trials on Addyi.
Share PDF:
Additional Resources:
- Addyi Consumer Alert: An emergency consumer alert was issued to warn women of the dangers of Addyi. Learn why women should pass on the pink pill.
- Top 10 Things to Know: Whether you are thinking of speaking with your doctor about Addyi or interested in learning more about this new drug. Read List
- Report Reactions: Adverse reactions to Addyi should be reported to the Federal Drug Administration at FDA.gov/medwatch or call 1-800-FDA-1088.
